aTyr Pharma (NASDAQ:LIFE) announced its earnings results on Wednesday. The biotechnology company reported ($1.80) EPS for the quarter, beating the consensus estimate of ($2.74) by $0.94, Morningstar.com reports. The business had revenue of $0.09 million for the quarter.
LIFE stock traded up $0.07 during trading on Thursday, reaching $2.87. 905 shares of the stock were exchanged, compared to its average volume of 159,297. The business’s 50 day simple moving average is $3.67. aTyr Pharma has a twelve month low of $2.80 and a twelve month high of $12.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.00 and a current ratio of 4.00.
Separately, ValuEngine upgraded aTyr Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. aTyr Pharma currently has a consensus rating of “Buy” and a consensus target price of $14.18.
A number of hedge funds have recently bought and sold shares of LIFE. Renaissance Technologies LLC raised its stake in aTyr Pharma by 19.8% during the 2nd quarter. Renaissance Technologies LLC now owns 1,845,873 shares of the biotechnology company’s stock worth $676,000 after buying an additional 305,314 shares during the period. Wedbush Securities Inc. raised its stake in shares of aTyr Pharma by 158.7% in the second quarter. Wedbush Securities Inc. now owns 67,270 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 41,271 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of aTyr Pharma by 1.9% in the second quarter. Vanguard Group Inc. now owns 1,779,024 shares of the biotechnology company’s stock worth $652,000 after purchasing an additional 33,702 shares during the last quarter.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Featured Article: What does it mean to hold a stock in street name?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.